Allied Market Research


Attention Deficit Hyperactivity Syndrome Market

Attention Deficit Hyperactivity Syndrome Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Type and by Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global attention deficit hyperactivity syndrome market is experiencing a significant growth, and will grow considerably in the next few years. Attention (ADHD) is a disorder in which an individual faces problems such as lack of persistence, lesser focusing capability, being disorganized, sometimes excessively fidgets, taps or talks. In addition to this, they may also perform hasty actions, which are quick enough and are not thought about at first hand by the individual or even have a desire for receiving immediate rewards or inability to delay gratification. This behavior hinders ability of the affected person in participating in social activities whether in schools or in jobs. This is among the common mental disorder seen nowadays. The risk factors associated with ADHD include, brain injuries, exposure to harmful environment during pregnancy, genetic related problems. The growing concern of the individuals for better quality of life will propel the industry in the coming years.

COVID-19 scenario analysis:

Pharmaceutical and biotech companies collaborated with governments around the globe in order to address the COVID-19 outbreak, starting from supporting the development of vaccines to planning for medicines supply chain challenges. The key institutes have developed around 115 vaccine candidates and 155 molecules are in the R&D pipeline. The commonly used drugs for malaria such as Hydroxychloroquine have witnessed dramatic surge in demand due to its effectiveness for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Since there is a surge in demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Rise in awareness about mental health among the global population and the initiatives taken by the government for early detection and treatment of attention deficit hyperactivity disorder are anticipated to help the market grow in the coming years. Furthermore, growth in number of individuals facing the mental disorders is also expected to propel the market during the forecast period. The increase in the investments on R&D of the new drugs for the treatment of ADHD is also expected to boost the market in the commenced period. The recent product launches for the therapy of this disease and the rise in number of pre-term births causing Attention Deficit Hyperactivity Syndrome are expected to boost the growth of the market. However, lack of awareness in the developing countries may hinder the growth of the industry in the near future.

The global market trends are as follows:

New product launches to boost the market

The key market players are focusing more on R&D of the products to capture the maximum shares in the coming years. Additionally, they are keen to introduce advancements in the products and launch the same in the market, which is expected to help the market flourish in the forecast period. For instance, on March 2019, ANI Pharmaceuticals, Inc. had announced that it has launched Methylphenidate Hydrochloride Extended-Release Tablet of 18 and 27 mg for the treatment of Attention Deficit Hyperactivity Syndrome.

The change in the dosage forms has massively affected on the patient’s response to the drug and hence faster curability rate, which is the rising concern of the individuals undergoing treatment. Among the major key player, Lanett on April 2019 announced that it had planned to launch the generic version for the ADHD treatment into the market. The rise in the product launches hence would gain attention of majority of the vendors and hence the market leaders are expected to gain maximum revenue from the product launches.

Surge in pre-term births will flourish the market

Rise in the number of pre-term births would help the industries to gain higher revenue.  The pre-term births and low weight after delivery are amongst the causes of the Attention Deficit Hyperactivity Syndrome. According to the estimates given by the World Health Organization in 2018, 15 million babies are born preterm that is, before the completion of the 37 weeks of gestation and is also stating that the figures will rise in the coming years. Furthermore, according to the data given by the National Institute of Health in 2018, the association of pre-terminal births with the Attention Deficit Hyperactivity Syndrome has been found out.

Additionally, furthermore, the hike in the rate of pregnant women consuming alcohol, cigarette and other drugs, which directly are teratogenic are anticipated to result into rise in incidence of ADHD. The growth such habits would result in the market to flourish during the forecast period. Moreover, the growth in the pre-term births and low weight births of the babies are also important factors, which are expected to propel the market in the coming years.

Key benefits of the report:

  • This study presents the analytical depiction of the global attention deficit hyperactivity syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global attention deficit hyperactivity syndrome market share.
  • The current market is quantitatively analyzed to highlight the global attention deficit hyperactivity syndrome market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global attention deficit hyperactivity syndrome market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the attention deficit hyperactivity syndrome market research report:

  • Which are the leading market players active in the attention deficit hyperactivity syndrome market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Attention Deficit Hyperactivity Syndrome Market Report Highlights

Aspects Details
By Drug Type
  • Stimulant
  • Non-Stimulant
  • Others
By Distribution channel
  • Hospital pharmacies
  • Retail pharmacies
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players

Eli Lilly and Company, Novartis AG, Purdue Pharma L.P., Pfizer Inc., GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, UCB S.A.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Attention Deficit Hyperactivity Syndrome Market

Global Opportunity Analysis and Industry Forecast, 2023-2032